Located in Heidelberg, Bioassay provides potency assays and functional bioassays, Good Laboratory Practices (GLP) compliant services and, through PSL, peptide synthesis services.

Reaction said the acquisition will expand its presence in Germany, while also enabling its global customers to leverage Bioassay’s expansive portfolio of regulated clinical and commercial services.

“Market demand is increasing globally for large molecule services as biopharmaceutical companies search for new treatment options for patients suffering with cancer and other serious diseases,” said Reaction’s CEO John Johnson.

“This transaction,” the CEO added, “enables Reaction Biology to add Bioassay’s impressive clinical-phase and post-approval infrastructure, which includes large molecule capabilities, as well as its GMP and GLP accreditations, to its expanding suite of drug discovery and development services. We can now provide our customers with even broader offerings to meet their research and development goals.”

Just last month, Reaction closed on the purchase of VivoPharm, a subsidiary of US biotech Vyant Bio. Reaction paid $5.5 million for VivoPharm, which is located in Hershey, Pennsylvania, gaining laboratory facilities, cell lines and capabilities in pharmacology, toxicology, pathology and bioanalytics.

Johnson said VivoPharm’s US operations are highly complementary to Reaction’s existing suite of drug discovery CRO services, which will allow it to build on its legacy. It is also “an important step in our roadmap for fully realizing Reaction’s potential as a provider of solutions for discovery and development of new drug candidates.”

Author: Elaine Burridge, Freelance Journalist